KR0163423B1 - 신규한 다공성 제약학적 형태 및 그의 제조방법 - Google Patents

신규한 다공성 제약학적 형태 및 그의 제조방법 Download PDF

Info

Publication number
KR0163423B1
KR0163423B1 KR1019900007369A KR900007369A KR0163423B1 KR 0163423 B1 KR0163423 B1 KR 0163423B1 KR 1019900007369 A KR1019900007369 A KR 1019900007369A KR 900007369 A KR900007369 A KR 900007369A KR 0163423 B1 KR0163423 B1 KR 0163423B1
Authority
KR
South Korea
Prior art keywords
paste
freeze
active substance
pharmaceutical form
dried
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019900007369A
Other languages
English (en)
Korean (ko)
Other versions
KR900017570A (ko
Inventor
꾸떠렐 프레더릭
반오이브 마갤리
Original Assignee
쟈끄 서비너
로오느-푸우랜크 상뜨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쟈끄 서비너, 로오느-푸우랜크 상뜨 filed Critical 쟈끄 서비너
Publication of KR900017570A publication Critical patent/KR900017570A/ko
Application granted granted Critical
Publication of KR0163423B1 publication Critical patent/KR0163423B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Filtering Materials (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1019900007369A 1989-05-24 1990-05-22 신규한 다공성 제약학적 형태 및 그의 제조방법 Expired - Fee Related KR0163423B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR8906781 1989-05-24
FR8906.781 1989-05-24
FR8906781A FR2647343B1 (fr) 1989-05-24 1989-05-24 Nouvelle forme pharmaceutique poreuse et sa preparation

Publications (2)

Publication Number Publication Date
KR900017570A KR900017570A (ko) 1990-12-19
KR0163423B1 true KR0163423B1 (ko) 1998-12-01

Family

ID=9381955

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900007369A Expired - Fee Related KR0163423B1 (ko) 1989-05-24 1990-05-22 신규한 다공성 제약학적 형태 및 그의 제조방법

Country Status (24)

Country Link
US (1) US5244881A (enExample)
EP (2) EP0399902B1 (enExample)
JP (1) JP2948271B2 (enExample)
KR (1) KR0163423B1 (enExample)
AT (2) ATE83663T1 (enExample)
AU (2) AU623779B2 (enExample)
CA (2) CA2017360A1 (enExample)
DD (1) DD297915A5 (enExample)
DE (2) DE69000641T2 (enExample)
DK (2) DK0399902T3 (enExample)
ES (2) ES2062437T3 (enExample)
FI (1) FI103712B (enExample)
FR (1) FR2647343B1 (enExample)
GR (1) GR3006655T3 (enExample)
IE (2) IE64370B1 (enExample)
IL (2) IL94459A (enExample)
NO (1) NO180517C (enExample)
NZ (2) NZ233766A (enExample)
PL (1) PL285327A1 (enExample)
PT (2) PT94138B (enExample)
TW (1) TW257672B (enExample)
WO (1) WO1990014089A1 (enExample)
YU (1) YU100790A (enExample)
ZA (2) ZA903895B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69231457T2 (de) * 1991-06-21 2001-05-23 Takeda Chemical Industries Ltd Zyklodextrin-Zusammensetzung enthaltend Fumagillol-Derivate
WO1993012769A1 (fr) 1991-12-24 1993-07-08 Yamanouchi Pharmaceutical Co., Ltd. Preparation se desagrageant dans la bouche et elaboration de cette preparation
GB9318880D0 (en) * 1993-09-11 1993-10-27 Smithkline Beecham Plc Pharmaceutical composition
EP0760680A1 (en) * 1994-05-27 1997-03-12 Farmarc Nederland Bv Pharmaceutical composition
CA2281473C (en) * 1997-02-20 2007-01-16 Therics, Inc. Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
BE1011251A3 (fr) * 1997-07-03 1999-06-01 Ucb Sa Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine.
TW527195B (en) 1997-10-09 2003-04-11 Ssp Co Ltd Fast-soluble solid pharmaceutical combinations
DK1052974T3 (da) * 1998-02-05 2009-08-10 Novartis Ag Farmaceutisk sammensætning indeholdende epothilon
IT1304190B1 (it) * 1998-12-18 2001-03-08 Euphar Group Srl Clatrati di deidroepiandrosterone e relative composizionifarmaceutiche
US6287603B1 (en) * 1999-09-16 2001-09-11 Nestec S.A. Cyclodextrin flavor delivery systems
NZ534039A (en) 2002-01-15 2006-08-31 Ucb Farchim S Formulations of pharmaceutical compositions for oral administration
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
EA200401111A1 (ru) 2002-02-25 2005-02-24 Диффьюжн Фармасьютикалз Ллс Биполярные соли транс-каротиноидов и их применение
DE10239531A1 (de) * 2002-08-23 2004-03-04 Gulbins, Erich, Prof. Dr. Prophylaxe und Therapie von Infektionserkrankungen
DE10248314A1 (de) * 2002-10-16 2004-04-29 Dr. Suwelack Skin & Health Care Ag Verwendung von Formkörpern zur äußeren Anwendung
FR2876910B1 (fr) * 2004-10-21 2007-04-13 Pierre Fabre Medicament Sa Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction
MX2007010359A (es) 2005-02-24 2008-04-04 Diffusion Pharmaceuticals Llc Trans carotenoides, su sintesis, formulacion y usos.
DE102005041860A1 (de) * 2005-09-02 2007-03-08 Schering Ag Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen
MX2009010988A (es) 2007-04-13 2010-03-15 Diffusion Pharmaceuticals Llc Uso de trans-carotenoides bipolares como un tratamiento previo y en el tratamiento de una enfermedad vascular periferica.
JP2009091309A (ja) * 2007-10-10 2009-04-30 Japan Organo Co Ltd バコパモニエラエキスを含有する組成物およびその製造方法ならびに飲食品
CN101878040A (zh) 2007-10-31 2010-11-03 扩散药品有限公司 一类促进小分子扩散的新型治疗剂
RU2011112926A (ru) * 2008-09-05 2012-10-10 МакНЕЙЛ-ППС, ИНК. (US) Способ изготовления таблеток цетиризина
EP3539542B1 (en) 2009-06-22 2023-04-19 Diffusion Pharmaceuticals LLC Diffusion enhancing compounds and their use with a thrombolytic
WO2011152869A1 (en) 2010-06-02 2011-12-08 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
SG10201507554RA (en) * 2010-09-13 2015-10-29 Bev Rx Inc Aqueous drug delivery system comprising off - flavor masking agent
RU2609198C1 (ru) * 2016-01-25 2017-01-30 Закрытое Акционерное Общество "БИОКОМ" Твердая лекарственная форма имипрамина немедленного высвобождения и способ ее получения
CA3018550A1 (en) 2016-03-24 2017-09-28 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5443570B2 (enExample) * 1972-10-27 1979-12-20
IE45770B1 (en) * 1976-10-06 1982-11-17 Wyeth John & Brother Ltd Pharmaceutical dosage forms
US4165382A (en) * 1977-10-17 1979-08-21 Jose Pozuelo Method of pharmacologically treating schizophrenia with alpha-methyl-para-tyrosine
US4349472A (en) * 1979-04-27 1982-09-14 Schering Corporation (S)-8(1-Adamantanecarbonyloxy)-7-chloro-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine
US4284555A (en) * 1979-04-27 1981-08-18 Schering Corporation 7-Chloro-8(substituted amino carbonyloxy)-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines
US4477378A (en) * 1980-02-05 1984-10-16 Schering Corp. Esters of substituted 8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines
EP0204003A4 (en) * 1984-11-27 1987-06-03 Dainippon Pharmaceutical Co 2-(1-piperazinyl)-4-substituted phenylquinoline derivatives, process for their preparation, and medicinal composition containing same.
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition

Also Published As

Publication number Publication date
FI103712B1 (fi) 1999-08-31
DE69005359D1 (de) 1994-02-03
IE901821L (en) 1990-11-24
TW257672B (enExample) 1995-09-21
IL94459A0 (en) 1991-03-10
AU5582890A (en) 1991-01-10
ATE98867T1 (de) 1994-01-15
CA2017355A1 (fr) 1990-11-24
ES2062437T3 (es) 1994-12-16
YU100790A (en) 1992-05-28
FI902553A0 (fi) 1990-05-23
ES2054289T3 (es) 1994-08-01
AU623779B2 (en) 1992-05-21
DK0399903T3 (da) 1993-02-08
ZA903978B (en) 1991-03-27
US5244881A (en) 1993-09-14
KR900017570A (ko) 1990-12-19
FR2647343A1 (fr) 1990-11-30
ATE83663T1 (de) 1993-01-15
JP2948271B2 (ja) 1999-09-13
IE901862L (en) 1990-11-24
FR2647343B1 (fr) 1994-05-06
EP0399902A1 (fr) 1990-11-28
FI103712B (fi) 1999-08-31
NO902280L (no) 1990-11-26
IL94459A (en) 1995-01-24
PT94138A (pt) 1991-01-08
WO1990014089A1 (fr) 1990-11-29
AU5743390A (en) 1990-12-18
IE64370B1 (en) 1995-07-26
PT94139A (pt) 1991-01-08
DE69000641D1 (de) 1993-02-04
IE63317B1 (en) 1995-04-05
PT94138B (pt) 1996-12-31
DK0399902T3 (da) 1994-02-14
AU631888B2 (en) 1992-12-10
CA2017360A1 (fr) 1990-11-24
IL94460A0 (en) 1991-03-10
GR3006655T3 (enExample) 1993-06-30
EP0399902B1 (fr) 1993-12-22
NO180517C (no) 1997-05-07
DE69000641T2 (de) 1993-06-09
NO902280D0 (no) 1990-05-23
NZ233784A (en) 1993-04-28
EP0399903A1 (fr) 1990-11-28
ZA903895B (en) 1991-03-27
NO180517B (no) 1997-01-27
PT94139B (pt) 1996-12-31
JPH0356412A (ja) 1991-03-12
NZ233766A (en) 1991-08-27
PL285327A1 (en) 1991-02-11
DE69005359T2 (de) 1994-05-05
DD297915A5 (de) 1992-01-30
EP0399903B1 (fr) 1992-12-23

Similar Documents

Publication Publication Date Title
KR0163423B1 (ko) 신규한 다공성 제약학적 형태 및 그의 제조방법
US5206025A (en) Porous pharmaceutical form and its preparation
US4835187A (en) Spray dried ibuprofen
EP0582396B1 (en) Taste-masking composition of bitter pharmaceutical agents
JP4336021B2 (ja) 口腔内崩壊型錠剤およびその製造法
KR890002949B1 (ko) 경구용 약제 조성물의 제조방법
US5505959A (en) Pharmaceutical composition in gel form in a dispensing package
IE59106B1 (en) A therapeutic effervescent composition and a method of preparing the same
JPH10510817A (ja) チュアブル製剤
EP0753296A2 (en) Oral formulations of S(+)-ibuprofen
EP0267702A2 (en) Spray dried acetaminophen
KR20010111565A (ko) 무젤라틴의 급속 분산성 투여 형태
KR950013752B1 (ko) 분무 건조된 아세트아미노펜의 치료용 분말, 이의 제조방법 및 이를 함유하는 약제학적 제형
DE4221880A1 (de) Feste und flüssige Lösungen von schwer wasserlöslichen Arzneistoffen
IL102198A (en) Pharmaceutical composition containing megestrol acetate
CN115212179A (zh) 一种3d打印凝胶基质及其制备方法和其应用
JPH0717866A (ja) 医薬組成物
JPH035438A (ja) フルルビプロフェン包接化合物およびこの包接化合物を用いる消炎鎮痛剤
KR20050026527A (ko) 젤리 형태의 한방 의약조성물
WO2005084703A1 (ja) 徐放性の口腔用組成物
JP4634589B2 (ja) 食品又は医薬品易服用化剤
CN115089618A (zh) 一种用于防治骨质疏松的药物组合物及其制备方法
JP2008133294A (ja) 口腔内崩壊型錠剤
CN109602699B (zh) 小儿连翘苷连翘脂素及其衍生物的注射剂
JPS58198416A (ja) セフアレキシンドライシロツプ剤の製造法

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20010908

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20010908